• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Biogen named Global Biotechnology Industry Leader

Biogen named Global Biotechnology Industry Leader

September 14, 2015
CenterWatch Staff

Biogen, based in Cambridge, Mass., has been named the biotechnology industry leader on the Dow Jones Sustainability World Index (DJSI World) for the second year in a row, after becoming the first U.S.-based biotech company to make the list in 2013. The company also was named to the Dow Jones Sustainability Index North America for the sixth consecutive year, one of only three biotech companies included.

DJSI World tracks the economic, environmental and social strategy and performance of the 2,500 largest companies in the S&P Global Broad Market Index. Of the 317 companies that were named to DJSI World, Biogen led the biotechnology industry, scoring in the 100th percentile on 17 of the 24 overall evaluation criteria, including those addressing patient access to treatments, environment and innovation.

“The same intellectual discipline and rigor that drives our science is reflected in our corporate citizenship,” said George A. Scangos, Ph.D., chief executive officer of Biogen. “Our industry leadership on the DJSI World is a testament to our company’s commitment to patients, the environment, our employees and the communities where we work and live.”

Biogen improved its DJSI score from last year on 11 specific environmental, social and economic indicators. Those indicators are climate strategy, addressing cost burden, health outcome contribution, labor practices and human rights, occupational health and safety, social reporting, stakeholder engagement, crisis and risk management, supply chain management, innovation management and customer relationship management.

Biogen also announced this year that it has become carbon neutral, meaning the company has effectively neutralized all of the carbon emissions associated with its business.

Biogen publishes an annual Corporate Citizenship Report based on internationally recognized Global Reporting Initiative (GRI) G4 Guidelines. In its most recent report, the company outlined a set of aggressive goals for 2020. Those goals include reducing greenhouse gas emissions and water use intensity by 80% (compared to its 2006 baseline and normalized by revenue) and driving down its “days away case rate,” by 80%, a widely recognized indicator of occupational safety performance. The company also is working to achieve zero waste-to-landfill status after keeping 99% of its waste from landfills since 2012.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing